Sanofi-aventis Announces Launch of New Blood Glucose Monitoring Devices BGStar and iBGStarTM
Sanofi-aventis announced the upcoming launch of the blood glucose monitoring (BGM) devices BGStar and iBGStarTM, developed by sanofi-aventis and its partner AgaMatrix. Due to their convenience, accuracy and ease-of-use, BGStar and iBGStarTM will help the decision-making process for people with diabetes and their healthcare professionals...
Novo Nordisk Logo
Type 2 Diabetes Patients Prefer Injectable Victoza to Oral Januvia
New Patient Reported Outcomes (PRO) data presented by today at the European Association for the Study of Diabetes (EASD) congress in Stockholm challenge the widespread perception that patients prefer oral to injected glucose-lowering therapies. Results from the 26-week, open-label study show that patients taking injectable Victoza (liraglutide 1.8 mg) reported significantly higher overall treatment satisfaction after 26 weeks than...
Bristol-Myers Logo
New Investigational Drug Improved HbA1c in Adults with Type 2 Diabetes
Bristol-Myers Squibb Company and AstraZeneca announced results from a randomized, double blind Phase 3 clinical study, which demonstrated that the addition of the investigational drug dapagliflozin to existing glimepiride (sulphonylurea) therapy produced significant reductions in HbA1c in adult patients with type 2 diabetes compared to glimepiride alone...
Sanofi-aventis’ Once-Daily Type 2 Diabetes Drug Lixisenatide Shows Significant Improvement in Glucose Control
Sanofi-aventis announced the first Phase III results of the GetGoal clinical trial program assessing the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist, as monotherapy in patients with type 2 diabetes. These results were presented at the European Association for the Study of Diabetes (EASD) 46th Annual Meeting in Stockholm, Sweden...
Looking Forward
There’s only one way to say it, folks:  I’m nervous.  I am now one week away from the Black Diamond sprint triathlon and I’m nervous.  I’m very excited,…
Blueberries Keep Getting Better
According to a new study published in the October issue of The Journal of Nutrition, daily consumption of whole blueberries increases insulin…
Takeda_Logo
Actos Ongoing FDA Safety Review: Potential Increased Risk of Bladder Cancer
The FDA notified healthcare professionals and patients that the Agency is reviewing data from an ongoing, ten-year epidemiological study designed to evaluate whether Actos (pioglitazone) is associated with an increased risk of bladder cancer. Findings from studies in animals and humans suggest this is a potential safety risk that needs further study. At this time, FDA has not concluded that Actos increases the risk of bladder cancer...
aha_logo
New Blood Markers for Diabetes May Help Identify Patients at Risk
Scientists have found that blood levels of some ribonucleic acids (microRNAs) are different among people with type 2 diabetes and those who subsequently develop the disease compared to healthy controls, according to research reported in Circulation Research: Journal of the American Heart Association...